Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Published: May 11, 2025 by: Reuters
Sentiment: Positive
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.
Read More
Novo Nordisk: It's Not Been This Cheap For Many Years
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Despite setbacks, Novo is actively enhancing market access for Wegovy and partnering with CVS and telehealth platforms to regain momentum. NVO's valuation is at a multi-year low, pointing to a plausible recovery if it manages to improve its execution and stem further losses.
Read More
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Read More
Novo Nordisk (NVO) Upgraded to Buy: Here's What You Should Know
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Novo Nordisk (NVO) is a Top Dividend Stock Right Now: Should You Buy?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Read More
Does Novo Nordisk (NVO) Have the Potential to Rally 51.24% as Wall Street Analysts Expect?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 51.2% upside potential for Novo Nordisk (NVO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers
Published: May 08, 2025 by: Fast Company
Sentiment: Positive
One day after WeightWatchers said that it would file for bankruptcy, weight-loss drug giant Novo Nordisk's outlook is brightening.
Read More
GLP-1 competition heats up: Novo Nordisk CEO talks Wegovy, CVS deal, earnings
Published: May 07, 2025 by: Yahoo Finance
Sentiment: Positive
Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94).
Read More
Novo Nordisk A/S (NVO) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk A/S (NVO) Q1 2025 Results Conference Call May 7, 2025 7:00 AM ET Company Participants Jacob Rode - Head of Investor Relations Lars Jorgensen - President and Chief Executive Officer David Moore - Executive Vice President, U.S. Operations and Global Business Development Mike Doustdar - Executive VP of International Operations Martin Holst Lange - Executive Vice President and Head of Development Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer Conference Call Participants Richard Vosser - JPMorgan Chase & Co. James Quigley - Goldman Sachs Peter Verdault - BNP Paribas Martin Parkhoi - SEB Michael Nedelcovych …
Read More
Why Novo Nordisk Stock Popped After Earnings
Published: May 07, 2025 by: The Motley Fool
Sentiment: Positive
GLP-1 drugmaker Novo Nordisk's (NVO 2.01%) stock jumped at the open and remains up 3.2% as of 10:20 a.m. ET after the company reported earnings this morning.
Read More
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.
Read More
Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S announced its Q1 earnings today, blaming a slight revenue miss on sales of compounded semaglutide. Q1 2025 earnings showed revenue of ~$11.9bn, operating profit of $5.9bn, with diluted EPS up 15% year-on-year. ~65% of revenues were driven by semaglutide, or Wegovy (obesity)/Ozempic (diabetes). This is truly a miraculous drug, and as compounded versions of semaglutide cease to be manufactured, performance will improve in 2H25.
Read More
SMCI Miss "Across the Board," NVO Wegovy Sales Up 85%, ANET Down on Beat
Published: May 07, 2025 by: Schwab Network
Sentiment: Negative
Diane King Hall discusses the biggest earnings movers this morning, including Novo Nordisk (NVO), which saw a 85% year-over-year increase in Wegovy sales but still trimmed guidance. Supermicro (SMCI) "missed across the board" in its earnings and trimmed guidance.
Read More
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Published: May 07, 2025 by: CNBC
Sentiment: Neutral
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Read More
Novo Nordisk investors relieved after expected guidance cut
Published: May 07, 2025 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) first-quarter results offered few surprises, but they may just have delivered the market something it needed more: relief. That collective anxiety release was reflected in the share price, which rose 4%.
Read More
Novo Blames Compounders As It Cuts 2025 Forecast. Shares Jump.
Published: May 07, 2025 by: Investors Business Daily
Sentiment: Negative
Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due what Novo says is illegal compounding of GLP-1 medicines.
Read More
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Positive
Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise, defying the 55% stock drop. Novo Nordisk's profitability and growth in emerging markets, coupled with a forward P/E ratio of 16.35x, make it an undervalued investment opportunity. Market concerns over minor market share losses are overblown; NVO remains the leader in a rapidly growing obesity and diabetes market.
Read More
Novo Nordisk Stock Jumps Despite Full-Year Outlook Cut
Published: May 07, 2025 by: Investopedia
Sentiment: Neutral
U.S.-listed shares of Novo Nordisk (NVO) are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook.
Read More
Novo Nordisk CEO says 'compounders took a part of our business away'
Published: May 07, 2025 by: CNBC International TV
Sentiment: Neutral
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in on the impact of compounded drugs on first-quarter Wegovy sales while forecasting a rebound later this year.
Read More
Drugmaker Novo Nordisk drops gender representation requirements in the US
Published: May 07, 2025 by: Reuters
Sentiment: Neutral
Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for its U.S. business following executive orders by President Donald Trump to stop diversity, equity and inclusion initiatives.
Read More
Novo Nordisk shares are rising after the company cut its outlook. It's been that kind of year.
Published: May 07, 2025 by: Market Watch
Sentiment: Neutral
Novo Nordisk is managing the unusual feat of seeing its stock price rise after reducing its earnings outlook.
Read More
Novo Nordisk shares rise despite cut to 2025 outlook
Published: May 07, 2025 by: Proactive Investors
Sentiment: Positive
Investors breathed a sigh of relief on Wednesday as shares in Novo Nordisk (NYSE:NVO) rose 3% in early trading, despite the drugmaker trimming its sales and profit forecasts for 2025. The downgrade, which had largely been anticipated, brings an end to a four-year streak of upgrades driven by booming demand for its obesity drug Wegovy.
Read More
Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales
Published: May 07, 2025 by: WSJ
Sentiment: Negative
The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, particularly in the U.S.
Read More
Novo Nordisk cuts 2025 guidance on weaker-than-expected Wegovy sales, posts first-quarter profit beat
Published: May 07, 2025 by: CNBC
Sentiment: Negative
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Read More
Obesity drugmaker Novo Nordisk cuts 2025 outlook, posts Q1 profit above forecast
Published: May 07, 2025 by: Reuters
Sentiment: Neutral
Obesity drugmaker Novo Nordisk on Wednesday posted first-quarter operating profit above analyst forecasts and cut its operating profit and sales outlook for the year.
Read More
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
7 May 2025 - Financial report for the period 1 January 2025 to 31 March 2025
Read More
Pharma sector still investable, faces added headwinds, says BMO's Siegerman
Published: May 06, 2025 by: CNBC Television
Sentiment: Neutral
Evan Siegerman, BMO Capital Markets, joins 'Fast Money' to talk new headwinds facing the pharma sector.
Read More
Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share.
Published: May 06, 2025 by: Barrons
Sentiment: Negative
Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has brought stumbles for Novo over the past year.
Read More
Why Novo Nordisk (NVO) is a Top Momentum Stock for the Long-Term
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 6 May 2025 – Novo Nordisk today announced that new data spanning the company's industry-leading portfolio across metabolic and cardiovascular health will be presented at the upcoming 32nd European Congress on Obesity (ECO), 11–14 May 2025. The data will further extend the wide-ranging evidence base for semaglutide through real-world evidence studies and additional analysis of the landmark cardiovascular outcomes trial, SELECT, as well as part 1 of the phase 3 ESSENCE trial in metabolic dysfunction-associated steatohepatitis (MASH). Data will also be presented on the wider societal impacts of treating and preventing obesity, alongside analysis of the burden of …
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406